Key result
Dual antiplatelet therapy with aspirin and clopidogrel is linked to ocular hemorrhage after cataract surgery.
Why the study?
Increasing numbers of ophthalmic patients are being treated with combined aspirin and clopidogrel, raising concerns about ocular haemorrhage risk.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
Clopidogrel (Plavix, Bristol-Myers Squibb/Sanofi) is a thienopyridine with antiplatelet effects caused by its inhibition of ADP mediated platelet aggregation pathways.1 Both aspirin and clopidogrel have established benefits in the secondary prevention of fatal and non-fatal coronary and cerebrovascular events.1,2 The CURE study has concluded that combining low dose aspirin and clopidogrel in patients with acute coronary syndromes results in additional improvements in outcome over aspirin alone.3 We can therefore expect increasing numbers of ophthalmic patients who have been started on this combined treatment (“COM”). Departmental concerns were raised by experience with a 76 year old normotensive patient who was on COM. He …
No takes yet. Share an insight, caveat, or question.
Barry R. Davies (2004) conducted a case report in Cataract (n=1). Combined aspirin and clopidogrel was evaluated on Ocular haemorrhage. Combined aspirin and clopidogrel therapy was highlighted as a potential new risk factor for ocular haemorrhage based on a case of a 76-year-old cataract surgical patient.
Synapse has enriched 10 related papers. Consider them for comparative context: